Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?

The short answer: neither semaglutide nor tirzepatide is reliably the more affordable GLP-1, because both list in the four-figures-per-month range without insurance and your real cost depends on your coverage, your diagnosis and the manufacturer self-pay options open to you. Tirzepatide produces more weight loss on average (20.2% versus 13.7% of body weight at 72 weeks in the head-to-head SURMOUNT-5 trial, according to Aronne and colleagues in the New England Journal of Medicine, 2025), while semaglutide has a longer real-world track record, slightly easier access, and a similar rate of gastrointestinal side effects.

Both are once-weekly injections that work, and the “better” one depends on your goals, your tolerance for side effects, your budget, and what your prescriber can actually get you.

Semaglutide and tirzepatide at a glance

Semaglutide and tirzepatide are both once-weekly incretin medicines prescribed for type 2 diabetes and chronic weight management. The table below sets out the attributes most people compare first.

What each drug actually is

Both belong to a class of medicines called incretin mimetics, which copy the gut hormones your body releases after a meal. These hormones tell the pancreas to release insulin, slow how fast the stomach empties, and signal the brain that you are full.

Semaglutide mimics a single hormone, GLP-1 (glucagon-like peptide-1). It has been used for type 2 diabetes since 2017 and for weight management since 2021, so there is now a large body of real-world safety data behind it.

Tirzepatide is a newer, “dual agonist.” It mimics GLP-1 and a second hormone, GIP (glucose-dependent insulinotropic polypeptide). Hitting two receptors appears to give it an edge on both blood sugar and weight, which is the main reason it has generated so much attention.

Other members of the same family include liraglutide and dulaglutide, older GLP-1 receptor agonists, and retatrutide, an investigational triple agonist that also targets the glucagon receptor and is not FDA approved. The retatrutide treatment guide and the retatrutide vs tirzepatide comparison cover where that research stands.

Weight loss: how they compare head-to-head

In the pivotal obesity trials, semaglutide 2.4 mg (the STEP program) produced average weight loss of around 15% of body weight over 68 weeks. Tirzepatide 15 mg (the SURMOUNT-1 trial) produced roughly 20-22% over 72 weeks, with a meaningful share of participants losing more than a quarter of their body weight.

The two were also compared directly in people with type 2 diabetes in the SURPASS-2 trial, where tirzepatide beat semaglutide on both blood sugar control and weight reduction. On the evidence available today, tirzepatide wins on raw weight loss. That does not mean it is the right choice for everyone, because the most weight loss is not always the goal, and tolerability and cost matter just as much.

What did the SURMOUNT-5 head-to-head trial find?

SURMOUNT-5 was the first randomized trial to compare the two drugs directly in adults with obesity but without type 2 diabetes. According to Aronne and colleagues (NEJM, 2025), 751 participants took the highest dose they could tolerate for 72 weeks, and average weight loss was 20.2% with tirzepatide versus 13.7% with semaglutide. Waist circumference also fell more with tirzepatide.

The trial was open label and funded by the maker of tirzepatide, which is worth knowing when you weigh it. Its result still lines up with the separate placebo-controlled programs: SURMOUNT-1 (Jastreboff et al., NEJM, 2022) for tirzepatide and STEP 1 for semaglutide. More detail on the newer drug sits in the tirzepatide weight loss overview.

Blood sugar and type 2 diabetes

Both lower A1c (a three-month average of blood sugar) substantially, and both were originally developed as diabetes drugs. Tirzepatide tends to produce slightly larger A1c reductions, again thanks to the second hormone it targets. For someone whose primary goal is glycemic control, both are excellent; for someone who needs the largest possible reduction, tirzepatide has the edge.

In SURPASS-2, which ran for 40 weeks in 1,879 adults with type 2 diabetes, every tirzepatide dose lowered A1c more than semaglutide 1 mg, according to Frías and colleagues (NEJM, 2021).

Side effects and safety

The side-effect profiles are very similar because they work in similar ways. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually worst when starting or increasing the dose and tend to ease over time. Slow dose titration is the main tool for keeping them manageable.

Less common but more serious considerations apply to both drugs. They carry a boxed warning about a risk of thyroid C-cell tumors seen in rodent studies, so they are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis, gallbladder problems, and low blood sugar (especially when combined with other diabetes medicines) are also on the label. None of this is a reason to avoid them, but it is a reason to use them under medical supervision rather than from an unvetted source.

Which has worse GI side effects, tirzepatide or semaglutide?

Neither drug has clearly worse gastrointestinal side effects in head-to-head trials. In SURPASS-2, nausea was reported by 17 to 22% of people on tirzepatide and 18% on semaglutide, diarrhea by 13 to 16% and 12%, and vomiting by 6 to 10% and 8%, with most cases mild to moderate (Frías et al., NEJM, 2021). SURMOUNT-5 reported the same pattern in adults without diabetes: gastrointestinal events were the most common in both groups and clustered during dose escalation.

Higher tirzepatide doses sat at the top of each range, so the dose you reach matters more than the drug name. The semaglutide side effects guide covers practical ways people manage nausea and constipation during titration.

Dosing and how you take them

Both are given as a once-weekly subcutaneous injection using a small pen, and both are started low and increased gradually over several weeks to reduce side effects. Semaglutide also comes in a daily oral tablet (Rybelsus), although the oral form is mainly used for diabetes and is less potent for weight loss than the injection. Tirzepatide is injection-only.

The maintenance doses studied for weight management are 2.4 mg weekly for semaglutide and 10 to 15 mg weekly for tirzepatide, the doses used in the STEP and SURMOUNT trials.

Cost and access

Both are expensive without insurance, with list prices in the four-figures-per-month range, and coverage for weight loss specifically is inconsistent. Access also fluctuates: both drugs have moved in and out of shortage as demand has surged. Compounded versions have filled some of the gap at lower cost, but the regulatory picture around compounding changes frequently, so availability and legality vary by point in time and by provider. Price and supply, rather than effectiveness, are often what actually decides which drug a person ends up on.

Which is more affordable, semaglutide or tirzepatide?

Neither is consistently cheaper. Both carry list prices in the four-figures-per-month range, and the amount you pay is set by three things: whether your plan covers the drug for your diagnosis, whether you qualify for a manufacturer savings card or self-pay program, and which dose you need. Ask your prescriber and pharmacy to price both options for your exact plan before you choose, and see the semaglutide cost breakdown for how those pieces fit together.

Does insurance cover semaglutide or tirzepatide?

Coverage depends on the indication. Plans cover the diabetes brands for type 2 diabetes far more often than the weight-management brands for obesity alone. A second approved use can change the picture: the FDA approved semaglutide (Wegovy) in 2024 to lower the risk of heart attack and stroke in adults with heart disease and overweight, based on the SELECT trial (Lincoff et al., NEJM, 2023), and approved tirzepatide (Zepbound) in 2024 for moderate to severe obstructive sleep apnea in adults with obesity. The sleep apnea treatment guide explains how that condition is diagnosed.

Are compounded semaglutide and tirzepatide still available?

Compounded versions are no longer covered by the shortage exception that allowed wide copying. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and it has since clarified the narrow conditions under which compounders may still prepare them. Compounded products are not FDA approved and are not checked for quality the way approved drugs are. The compounded semaglutide guide and the compounded tirzepatide guide set out the questions to ask a clinic that offers them.

The muscle-loss caveat that applies to both

Rapid weight loss from any GLP-1 medicine is not purely fat. A significant portion of the weight lost can be lean muscle mass, which matters for metabolism, strength, and long-term weight maintenance. Anyone using these drugs should prioritize adequate protein intake and regular resistance training to protect muscle. This is one of the most overlooked parts of GLP-1 therapy and applies equally to semaglutide and tirzepatide.

The guide to GLP-1 muscle loss covers protein targets and strength training during treatment.

Who prescribes semaglutide and tirzepatide?

Semaglutide and tirzepatide are prescription drugs, so a licensed clinician has to evaluate you first. Primary care physicians, endocrinologists, obesity medicine physicians, nurse practitioners and physician assistants all prescribe them, in person or through telehealth. A careful prescriber reviews your history for thyroid cancer, pancreatitis and gallbladder disease, checks your other medicines, and plans follow-up visits for each dose step.

Some regenerative and functional health clinics also offer GLP-1 prescribing alongside services such as peptide therapy. You can browse clinics that list peptide therapy across the US and ask each one which GLP-1 medicines it prescribes, whether it uses FDA-approved brands or compounded products, and who supervises your dose changes. Listing order on Regenerated.com is not paid ranking, and being listed is not an endorsement.

Who each one is best for

• Tirzepatide may be the better fit if your main goal is maximum weight loss or the largest possible improvement in blood sugar, and you can access and afford it.
• Semaglutide may be the better fit if you value a longer real-world safety record, want the option of an oral version, or find it easier to obtain through your insurance or provider.
• Either is a reasonable starting point, and many people switch between them based on tolerance, results, and what is actually available.

The bottom line

Tirzepatide currently produces more weight loss and slightly better blood sugar control, while semaglutide offers a longer track record and a bit more flexibility. Both are genuinely effective tools, not magic, and both work best alongside nutrition, resistance training, and medical oversight. The right choice is the one you can access consistently and tolerate well, decided together with a qualified prescriber.

On price, neither drug wins by default: your insurance, your diagnosis and the self-pay options available to you decide which one costs less. On side effects, the two are close, with nausea, diarrhea and vomiting at similar rates in head-to-head trials.

Frequently asked questions

Is tirzepatide just a stronger version of semaglutide?

No, tirzepatide is a different molecule, not a stronger dose of semaglutide. Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both the GIP and GLP-1 receptors. That dual action is part of why tirzepatide produced more weight loss in the SURMOUNT-5 trial, 20.2% versus 13.7% at 72 weeks. The two drugs also use different dose scales, so milligram amounts cannot be compared directly, and a prescriber cannot convert one dose into the other.

Can you switch from semaglutide to tirzepatide?

Yes, switching from semaglutide to tirzepatide is common and is usually done under a prescriber’s guidance. Most prescribers restart tirzepatide at a low dose and titrate up over several weeks to manage side effects, rather than jumping straight to a high dose. People usually switch because of a weight loss plateau, side effects, cost or supply. The guide to GLP-1 weight loss plateaus covers what else to review before changing drugs.

Which has fewer side effects?

Semaglutide and tirzepatide have broadly similar side effects, with nausea, diarrhea, vomiting and constipation the most common for both. Individual tolerance varies, and slow dose increases matter more than the choice of drug. In SURPASS-2, nausea affected 18% of people on semaglutide and 17 to 22% on tirzepatide, with the higher figures at the top tirzepatide doses. Serious risks on the label, such as pancreatitis and gallbladder disease, are shared by both drugs.

Will the weight come back if I stop?

Studies of both drugs show that much of the lost weight tends to return after stopping, which is why they are generally viewed as long-term treatments rather than short courses. In SURMOUNT-4, adults switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, according to Aronne and colleagues (JAMA, 2024). Maintaining muscle and habits built during treatment helps.

Which is more affordable, semaglutide or tirzepatide?

Neither semaglutide nor tirzepatide is reliably more affordable. Both list in the four-figures-per-month range without insurance, and what you pay depends on whether your plan covers the drug for your diagnosis, whether you qualify for a manufacturer savings or self-pay program, and which dose you need. Compounded versions cost less but are not FDA approved, and their legal availability narrowed after the FDA declared both shortages resolved. Price both options for your plan before you decide.

Which has worse GI side effects, tirzepatide or semaglutide?

Neither has clearly worse gastrointestinal side effects. In the SURPASS-2 head-to-head trial, nausea was reported by 17 to 22% of people on tirzepatide and 18% on semaglutide, diarrhea by 13 to 16% and 12%, and vomiting by 6 to 10% and 8%. Most episodes were mild to moderate and happened while the dose was being increased. Higher tirzepatide doses sat at the top of each range, so a slower titration usually helps more than switching drugs.

Related reading

• Peptide Therapy: The Complete Guide
• Menopause and Weight Gain: What Actually Works
• NAD+ IV Therapy and Anti-Aging

This guide is for education and is not medical advice. GLP-1 medicines are prescription drugs with real risks and should be used under the supervision of a qualified healthcare provider.

Frequently Asked Questions

Which one leads to more weight loss, semaglutide or tirzepatide?

Tirzepatide leads to more weight loss than semaglutide. In the SURMOUNT-5 head-to-head trial, adults with obesity lost 20.2% of body weight on tirzepatide versus 13.7% on semaglutide over 72 weeks. Separate trials point the same way: semaglutide 2.4 mg produced around 15% in the STEP trials, and tirzepatide 15 mg produced roughly 20 to 22% in SURMOUNT-1. The right choice is still the one you can access consistently and tolerate well, decided with a qualified prescriber.

How are the two drugs different in how they work?

Semaglutide is a GLP-1 receptor agonist, meaning it mimics a single gut hormone, glucagon-like peptide-1. Tirzepatide is a dual GIP and GLP-1 receptor agonist, so it mimics two hormones that are released after meals. Both slow stomach emptying, raise insulin release when blood sugar is high and increase the feeling of fullness. Both lower A1c substantially, with tirzepatide tending to produce slightly larger A1c reductions in the SURPASS-2 trial.

What are the side effects and safety risks?

The most common side effects of both drugs are gastrointestinal: nausea, vomiting, diarrhea and constipation, usually worst when starting or increasing the dose. Both carry a boxed warning about thyroid C-cell tumors seen in rodent studies and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Other labeled risks include pancreatitis, gallbladder problems and low blood sugar, especially alongside insulin or sulfonylureas.

How much do semaglutide and tirzepatide cost?

Semaglutide and tirzepatide both list in the four-figures-per-month range without insurance, and coverage for weight loss specifically is inconsistent. Plans cover the diabetes brands for type 2 diabetes more often than the weight brands for obesity alone. Manufacturer savings cards and self-pay programs can lower the price for some people, and a second approved use, such as heart disease risk for semaglutide or sleep apnea for tirzepatide, can change coverage decisions.

How are they taken and are they FDA approved?

Both are given as a once-weekly subcutaneous injection, started low and increased gradually over several weeks. Semaglutide also comes as a daily oral tablet (Rybelsus), though it is less potent for weight loss than the injection. Semaglutide was FDA approved in 2017 for diabetes and 2021 for weight, while tirzepatide was approved in 2022 for diabetes and 2023 for weight. Compounded versions of either drug are not FDA approved.

Will I keep the weight off after stopping, and does the weight lost include muscle?

Much of the lost weight tends to return after stopping either drug: in SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of body weight over 52 weeks. Rapid weight loss from any GLP-1 medicine is also not purely fat, since a significant portion can be lean muscle mass. Prioritizing adequate protein intake and regular resistance training helps protect muscle and supports maintenance after the dose is lowered or stopped.